Views: 1,385 | Downloads:
25
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Phase II Study of Concurrent Chemoradiotherapy for Inoperable (Bulky) Stage III (AlB) Non-Small Cell Lung Cancer (NSCLC) : A Preliminary Report
Ratanatharathom V 
,
Lorvidhaya V ,
Kraipiboon P ,
Sirachainan E ,
Maoleekoonpairoj S ,
Phromratanapongse P ,
Cheirsilpa A ,
Tangkaratt S ,
Srimuninnimit V ,
Pattaranutapom P ,
Lertsanguansinchai P
,
Lorvidhaya V ,
Kraipiboon P ,
Sirachainan E ,
Maoleekoonpairoj S ,
Phromratanapongse P ,
Cheirsilpa A ,
Tangkaratt S ,
Srimuninnimit V ,
Pattaranutapom P ,
Lertsanguansinchai P We designed a phase II study to determine the fctsibility and toxicity of concomitant
radiotherapy and PaclitaxeVCarboplatin followed by adjuvant chemotherapy of the same regimen
in patients with newly diagnosed inoperable stage III
AlB
non-small cell lung cancer. Patients
were irradiated with a total dose of 66 Gy. Weekly courses of Paclitaxel 45 mg/m2 and Carbo-
platin AUC 2 were administered intravenously during the irradiation period. After completion of
concurrent chemoradiotherapy, adjuvant chemotherapy with Paclitaxel 175 mg/m2 and Carbo-
platin AUC 6 intravenously every 3 weeks for 4 cycles were given. Since March 1998, 15
patients have been enrolled. All patients were assessable for efficacy and toxicity after con-
current chemoradiotherapy. Eleven patients were assessable for efficacy and toxicity after
adjuvant chemotherapy. After concomitant chemoradiotherapy, complete response (CR) was
documented in 2 of 15 (13%). Partial response (PR) was documented in 9 of 15 (60%). After
completion of adjuvant chemotherapy in 11 patients, the overall response rate was 91 per cent.
(18% CR, 73% PR). There were 8 per cent gr. 3-4 neutropenia which occurred during adjuvant
chemotherapy. Concomitant Paclitaxel/Carboplatin and radiotherapy are promising modalities
in the treatment of inoperable stage III
AlB
non-small cell lung cancer.
Key word
:
Lung Cancer, Inoperable Non-Small Cell Lung Cancer, Concomitant (Concurrent)
Chemoradiotherapy
radiotherapy and PaclitaxeVCarboplatin followed by adjuvant chemotherapy of the same regimen
in patients with newly diagnosed inoperable stage III
AlB
non-small cell lung cancer. Patients
were irradiated with a total dose of 66 Gy. Weekly courses of Paclitaxel 45 mg/m2 and Carbo-
platin AUC 2 were administered intravenously during the irradiation period. After completion of
concurrent chemoradiotherapy, adjuvant chemotherapy with Paclitaxel 175 mg/m2 and Carbo-
platin AUC 6 intravenously every 3 weeks for 4 cycles were given. Since March 1998, 15
patients have been enrolled. All patients were assessable for efficacy and toxicity after con-
current chemoradiotherapy. Eleven patients were assessable for efficacy and toxicity after
adjuvant chemotherapy. After concomitant chemoradiotherapy, complete response (CR) was
documented in 2 of 15 (13%). Partial response (PR) was documented in 9 of 15 (60%). After
completion of adjuvant chemotherapy in 11 patients, the overall response rate was 91 per cent.
(18% CR, 73% PR). There were 8 per cent gr. 3-4 neutropenia which occurred during adjuvant
chemotherapy. Concomitant Paclitaxel/Carboplatin and radiotherapy are promising modalities
in the treatment of inoperable stage III
AlB
non-small cell lung cancer.
Key word
:
Lung Cancer, Inoperable Non-Small Cell Lung Cancer, Concomitant (Concurrent)
Chemoradiotherapy
Download:
PDF